Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24781350 | 0.78 | GAA (0.40) | GAANPC1MAPTNFKB1RAB9A | |
| SCHEMBL856112 | 0.78 | MET (0.38) | PIK3CDPIK3CAPIK3CBNPC1MAPT | |
| SCHEMBL30911731 | 0.76 | SLC2A1 (0.36) | — | |
| SCHEMBL23976319 | 0.75 | MAPK1 (0.39) | GAASMN1; SMN2 | |
| SCHEMBL23976976 | 0.74 | MET (0.41) | PIK3CDPIK3CAPIK3CBGAA | |
| SCHEMBL17979413 | 0.70 | GAA (0.32) | GAANPC1MAPTNFKB1RAB9A | |
| SCHEMBL29291060 | 0.70 | MAPT (0.37) | GAANPC1MAPTNFKB1RAB9A | |
| SCHEMBL29695090 | 0.70 | GAA (0.32) | GAANPC1MAPTNFKB1RAB9A | |
| SCHEMBL26598715 | 0.70 | GAA (0.32) | GAANPC1MAPTNFKB1RAB9A | |
| SCHEMBL28242275 | 0.69 | GRIN1 (0.35) | GAANPC1MAPTNFKB1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12226405-B2 | Compounds and compositions for inhibiting the activity of HIF2-alpha and their methods of use | NOVARTIS AG (CH) | 2025-02-18 | — | — | US | disclosed |
| EP-4143187-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-ALPHA AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-05-08 | — | — | EP | disclosed |
| EP-4143187-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-ALPHA AND THEIR METHODS OF USE | Novartis AG (CH) | 2023-03-08 | — | — | EP | disclosed |
| US-20220401422-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-22 | — | — | US | disclosed |
| US-20220401422-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-22 | — | — | US | disclosed |
| CN-115485275-A | Compounds and compositions that inhibit HIF 2-alpha activity and methods of use thereof | 诺华股份有限公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2021220170-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-ALPHA AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021217508-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2α AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12226405-B2 | Compounds and compositions for inhibiting the activity of HIF2-alpha and their methods of use | HIF1AN, HIF1A, EGLN2 | PIK3CD 1330/4885PIK3CA 803/4885PIK3CB 1224/4885 |
| US-20220401422-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE | HIF1AN, HIF1A, EGLN2 | PIK3CD 1330/4885PIK3CA 803/4885PIK3CB 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.